Moderna's Cancer Vaccine Shows Promise, Stock Valuation Raises Concerns
Moderna's stock has surged over 600% this year, reaching a market cap close to 90000 million dollars, driven by positive clinical trial results for its cancer vaccine, intismeran, developed in collaboration with Merck. On Aug. 19, phase 3 trial results indicated that intismeran, when combined with Merck's Keytruda, significantly reduced the risk of death and cancer recurrence in melanoma patients. Despite the promising results, the vaccine has not yet received approval, and there are concerns about the stock's inflated valuation. Investors may be overestimating the potential for intismeran to treat multiple cancers, which remains uncertain. Additionally, the production of a personalized cancer vaccine at scale poses operational challenges and costs. The profit-sharing agreement between Moderna and Merck could further limit Moderna's long-term profitability. Given these factors, the current stock price may not be sustainable, and potential investors should exercise caution.
-- Price
This content is provided for general informational purposes only and doesn't constitute financial, investment, legal, or tax advice. Any events, rewards, online promotions, or related information mentioned herein should not be considered a recommendation, solicitation, or invitation to purchase, sell, trade, or otherwise deal in any crypto assets. Crypto assets are highly volatile and may result in loss. The availability of WEEX services, products, and related events may vary by region. You are responsible for ensuring that your participation is in accordance with applicable local laws and regulations.
You may also like

Sellas Life Sciences Cancer Vaccine Extends Patient Survival in Blood Cancer Clinical Trial

NVIDIA Launches Nemotron for Science to Accelerate Scientific Discoveries with Intelligent Agents

FDA Rejects Approval of Kangfang Biotech's Cancer Drug Ivonescimab

Former Employee Sues Ethereum Foundation, Claims Retaliatory Dismissal After Protesting 'Seppuku' Clause

BRT.Fit Founder Calls for Incorporating Exercise Habits into Cancer Prevention

Nixo sues Ethereum Foundation, Vitalik Buterin over 'suicide pledge' claim

U.S. Senate Rejects Long-Term Regulation Legislation for the Cryptocurrency Industry

Proteomic clocks link accelerated aging to higher risk of death and disease

Aging is not linear: cells go through coordinated stages of deterioration

Trump and Islamophobia: The Chorus That No Longer Mobilizes Votes

Jennifer Tilly Earns Up to $10 Million a Year from The Simpsons Without Ever Participating: Her Story

Alphabet vs. Amazon: Which Is the Better AI Cloud Stock to Own for the Next 5 Years?

Worried About Nvidia? 3 Artificial Intelligence (AI) Stocks That May Be Safer Buys Right Now

Further Arrests in the Zondacrypto Scandal. Prosecutor Talks About Three Individuals

Bitcoin developer verifies 164 million unspent coins in just 72 seconds

4 Dates That Could Move the Stock Market in Epic Fashion This Week. Here's What Investors Need to Know.

CFTC puts tokenization and margin on Dec. 15 trading agenda

South Korea’s Toss Plans Ethereum Wallet for ETH, USDT and USDC Inside Its Finance App

Druckenmiller Turns Bearish on Copper Prices, Zeroes Out Stock Positions, Says Current Market Visibility is Lowest in Memory

From ETH to BTC: What is THORChain and what can investigators track

Tether’s Paolo Ardoino backs RGB for Bitcoin tokenization

Prediction: These Will Be Nvidia’s and AMD’s Stock Prices by the End of 2027 (Hint: Only 1 Is a Buy).

Trezor Warns 27,000 Shipping Orders Were Exposed in Partner Breach, Not Wallet Keys

Fed’s Waller says blockchain is forcing banks to compete

Solana Drops “Mainnet Beta” Label as Foundation Introduces Protocol Version 1.0

Where Will Nvidia Stock Be in 3 Years?

Hong Kong, SWIFT explore 24/7 tokenized deposit payments

Google uncovers AI hacking tool that turns security fixes into cyberattacks

Large Fried Chicken Franchisee Files for Chapter 11 Bankruptcy Protection







